Clinical trial NCT05800535: JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients
Official title: Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Cancer
Sarcopenia
Keywords: Post cancer
Chemobrain
Sarcopenia
Medical evaluation
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2023-04-05
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients who have been treated for cancer and who have completed the post-cancer assessment day

Brief summary: Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. Thus, the reconquest of a life after cancer becomes possible but raises many challenges for the patient, his entourage, the medical profession and our society. One of the major challenges is the detection and management of treatment side effects for all patients. In addition to the standard organic assessment (glycaemia, creatinine, liver test, blood count), we are mainly interested in muscle deconditioning and cognitive impairment, which are particularly disturbed in these populations. After the evaluation day, patients are referred to the most appropriate structures (Adapted physical activity, sports for health, and rehabilitation at Henry Gabriel Hospital).

JUMP research is part of axis 2 of the 2021-2030 cancer plan: "Limiting sequelae and improving quality of life", through sheets 1 (research) / 6 (access and quality) / 7 (prevention). This leads to the concrete implementation on the territory of adapted care channels in the city: medical structure, physiotherapy, Adapted Physical Activity (APA) structures, associative structures; which makes it possible to develop and strengthen the city-hospital link. Finally, it allows the patient to take ownership and get involved in the project, allowing in the future to make them truly active in they care and to advise and motivate their peers.

This study is non-interventional, it uses research on data that is already collected as part of conventional care, during the JUMP evaluation day.

This study allows the investigators to constitute a cohort of patients to study different parameters related to the disease or to the treatments received.

Our main objective in this study is to describe the muscular and neurocognitive impairment of post-cancer patients evaluated as part of the JUMP program.


Eligibility criteria: Inclusion Criteria:

* Age : 18 to 74 years
* localization of the primitive: breast, lung, melanoma, testicle, bladder, kidney, ovary, colon and pancreas, hemopathy
* patient who benefited from the post-cancer assessment day-

Exclusion Criteria:

* Under 18years
* Over 74 years
* Patient who did not received any chemical treatment
* Patient who do not wish to participate

Primary outcomes:
measure: Prevalence of patients with physical and neurocognitive impairment
timeFrame: at least 1 year later after chemical treatments
Secondary outcomes:
Other outcomes:
Locations:
city: Pierre-Bénite
country: France
facility: Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud
Study officials:
References: